FDA Approves Two Sickle Cell Disease Gene Therapies

The U.S. Food and Drug Administration (FDA) on Friday approved a pair of gene therapies for sickle cell disease, including the first treatment based on the breakthrough CRISPR gene editing technology.The agency approved Lyfgenia from bluebird bio, and a separate treatment…[#item_full_content]